Daniella Beckman is now the permanent chief financial officer of Tango Therapeutics after holding the role in an interim capacity. Her experience includes financial positions at Idenix Pharmaceuticals, Coley Pharmaceuticals, Biogen Idec, and PricewaterhouseCoopers. Cambridge, MA-based Tango recently raised $60 million in Series B financing to support continued development of cancer drugs based on a concept called synthetic lethality.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
